drugset / Trial / NCT07088822
A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of the study is to evaluate the safety and immunogenicity of a novel Venezuelan Equine Encephalitis virus (VEEV) vaccine (V4020) for the first time in humans compared to placebo when administered by subcutaneous or intramuscular injection.
Timeline
- Start
- 2025-08-15
- Primary completion
- 2026-02-28
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | V4020 | Vaccine | 1000 unknown | Subcutaneous |
| Subject | V4020 | Vaccine | 10000 unknown | Subcutaneous |
| Subject | V4020 | Vaccine | 100000 unknown | Subcutaneous |
| Subject | V4020 | Vaccine | 1e+06 unknown | Subcutaneous |